發(fā)布時(shí)間：2018-08-11 08:37

【摘要】：目的：通過(guò)回顧性研究分析我院肉瘤患者一般資料、臨床特征、治療方式、中醫(yī)證型及轉(zhuǎn)歸,為以后的科學(xué)研究提出思路和方向。方法：采用回顧性研究的方法,收集自2009年3月1日至2015年3月1日東方醫(yī)院腫瘤科病理診斷為肉瘤的住院患者病例。記錄其一般情況、腫瘤診斷信息、病史資料、治療情況及轉(zhuǎn)歸。應(yīng)用SPSS軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果：共收集到肉瘤患者54例,占我科6年間收治所有惡性腫瘤患者的1.41%,其中男26例,女28例。我院最常見(jiàn)的是平滑肌肉瘤,其次是纖維肉瘤、脂肪肉瘤。不同病理類(lèi)型在不同性別間有顯著差異。腫瘤部位上最常見(jiàn)為內(nèi)臟原發(fā)的肉瘤,其次為四肢�；颊呓^大多數(shù)為臨床Ⅲ期、Ⅳ期。最普遍的轉(zhuǎn)移部位是淋巴結(jié),其次是肺,但肺轉(zhuǎn)移獨(dú)立出現(xiàn)的幾率更高。在治療上,多數(shù)患者接受手術(shù)治療,僅2例患者接受靶向治療。氬氦刀與中藥治療作為我科特色被大部分患者接受,未失訪的7例患者平均治療后生存期為16.57個(gè)月,其中2例患者死亡,5例患者仍繼續(xù)在院治療。接受其他治療的4例患者平均治療后生存期為2.75個(gè)月。典型病例為Ⅳ期骨肉瘤外院多重治療后進(jìn)展患者,經(jīng)氬氦刀聯(lián)合中藥治療治療后生存19個(gè)月,療效顯著。結(jié)論：我院收治肉瘤患者總體發(fā)病率與文獻(xiàn)相符,但以臨床Ⅲ期、Ⅳ期為主,病理類(lèi)型及轉(zhuǎn)移部位與文獻(xiàn)報(bào)道有差異,這與我科氬氦刀聯(lián)合中藥的特色治療密切相關(guān)。氬氦刀聯(lián)合中藥治療的患者生存期相較于應(yīng)用其他治療患者有更長(zhǎng)的趨勢(shì),典型個(gè)案生存期相較文獻(xiàn)延長(zhǎng)。氬氦刀聯(lián)合中藥的治療模式值得進(jìn)一步研究。
[Abstract]:Objective: to analyze the general data, clinical characteristics, treatment methods, TCM syndromes and prognosis of sarcoma patients in our hospital. Methods: from March 1, 2009 to March 1, 2015, inpatients with sarcoma diagnosed by pathology in Department of Oncology, Oriental Hospital, were collected by retrospective study. Record its general information, tumor diagnosis information, medical history, treatment and outcome. SPSS software was used for statistical analysis. Results: a total of 54 cases of sarcoma were collected, accounting for 1.41% of all patients with malignant tumor treated in our department during the past 6 years, including 26 cases of males and 28 cases of females. Leiomyosarcoma is the most common in our hospital, followed by fibrosarcoma and liposarcoma. There were significant differences in different pathological types between sexes. Visceral primary sarcoma was the most common tumor, followed by limbs. Most of the patients were stage 鈪，

本文編號(hào)：2176466